Eiry  Roberts net worth and biography

Eiry Roberts Biography and Net Worth

Eiry W. Roberts, M.D. was appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and medical affairs activities at Neurocrine Biosciences. Dr. Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology, and metabolic diseases. She joined Neurocrine Biosciences from Eli Lilly and Company where she had worked since May 1991. During her tenure at Eli Lily and Company, Dr. Roberts held various positions of increasing responsibility, including Vice President, Clinical Pharmacology/Managing Director of Chorus, a position she held from October 2014 until December 2017 and Vice President of R&D, BioMedicines Business Unit. Dr. Roberts is a physician who trained in pharmacology and medicine in the UK, qualifying from the University of London in 1987. Her post-graduate clinical training was in clinical pharmacology and cardiology at St. Bartholomew’s Hospital and the Royal London Hospital. Dr. Roberts also serves as a director of Amicus Therapeutics, a clinical-stage biopharmaceutical company focused on rare diseases.

What is Eiry Roberts' net worth?

The estimated net worth of Eiry Roberts is at least $3.10 million as of February 13th, 2024. Dr. Roberts owns 23,716 shares of Neurocrine Biosciences stock worth more than $3,103,476 as of June 20th. This net worth approximation does not reflect any other assets that Dr. Roberts may own. Additionally, Dr. Roberts receives a salary of $1,120,000.00 as Insider at Neurocrine Biosciences. Learn More about Eiry Roberts' net worth.

How old is Eiry Roberts?

Dr. Roberts is currently 60 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Eiry Roberts' age.

What is Eiry Roberts' salary?

As the Insider of Neurocrine Biosciences, Inc., Dr. Roberts earns $1,120,000.00 per year. There are 2 executives that earn more than Dr. Roberts. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $2,050,000.00 per year. Learn More on Eiry Roberts' salary.

How do I contact Eiry Roberts?

The corporate mailing address for Dr. Roberts and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Eiry Roberts' contact information.

Has Eiry Roberts been buying or selling shares of Neurocrine Biosciences?

Eiry Roberts has not been actively trading shares of Neurocrine Biosciences in the last ninety days. Most recently, Eiry Roberts sold 1,114 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $132.96, for a transaction totalling $148,117.44. Following the completion of the sale, the insider now directly owns 23,716 shares of the company's stock, valued at $3,153,279.36. Learn More on Eiry Roberts' trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 48 times. They sold a total of 552,140 shares worth more than $72,817,248.22. The most recent insider tranaction occured on May, 29th when Director Stephen A Sherwin sold 40,000 shares worth more than $5,338,400.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 5/29/2024.

Eiry Roberts Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2024Sell1,114$132.96$148,117.4423,716View SEC Filing Icon  
1/31/2024Sell1,457$140.79$205,131.0320,832View SEC Filing Icon  
12/22/2023Sell10,000$126.74$1,267,400.0019,521View SEC Filing Icon  
12/12/2023Sell13,925$120.30$1,675,177.5029,521View SEC Filing Icon  
12/8/2023Sell300$120.10$36,030.0029,521View SEC Filing Icon  
4/24/2023Sell14,400$103.48$1,490,112.0026,644View SEC Filing Icon  
1/31/2023Sell1,457$109.99$160,255.4326,171View SEC Filing Icon  
1/10/2022Sell2,632$74.50$196,084.00View SEC Filing Icon  
2/8/2021Sell2,363$116.78$275,951.1417,231View SEC Filing Icon  
1/8/2021Sell2,632$111.06$292,309.9215,845View SEC Filing Icon  
8/5/2020Sell2,257$118.84$268,221.8811,446View SEC Filing Icon  
6/23/2020Sell5,000$130.00$650,000.0014,416View SEC Filing Icon  
4/24/2020Sell1,934$99.47$192,374.98View SEC Filing Icon  
2/7/2020Sell1,623$103.31$167,672.137,452View SEC Filing Icon  
1/8/2020Sell2,632$111.11$292,441.52View SEC Filing Icon  
1/8/2019Sell1,857$84.09$156,155.133,143View SEC Filing Icon  
See Full Table

Eiry Roberts Buying and Selling Activity at Neurocrine Biosciences

This chart shows Eiry Roberts's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $130.86
Low: $130.63
High: $136.50

50 Day Range

MA: $137.10
Low: $130.86
High: $143.19

2 Week Range

Now: $130.86
Low: $93.02
High: $148.37

Volume

1,013,019 shs

Average Volume

732,423 shs

Market Capitalization

$13.17 billion

P/E Ratio

36.05

Dividend Yield

N/A

Beta

0.36